Cognizin® Citicoline May Help Improve Attention in Healthy Adult Women: Clinical Study Findings
A 28-day study found that Cognizin® Citicoline may improve specific attention metrics in healthy middle-aged women, suggesting potential benefits for daily cognitive function.
Authors
Erin McGlade, Allison Locatelli, Julia Hardy, Toshikazu Kamiya, Masahiko Morita, Koji Morishita, Yoichiro Sugimura, and Deborah Yurgelun-Todd
Institution
Brain Institute, University of Utah, Salt Lake City, USA
Source
Food and Nutrition Sciences, 2012; 3: 769–773.
Abstract
Rationale
Citicoline has been studied for its potential to support cognitive function through mechanisms like phospholipid synthesis and brain cell signaling. While previous research has shown benefits in various populations, few studies have evaluated its effect on attentional performance in healthy adult women.
Objective
This study aimed to evaluate whether daily Cognizin® Citicoline supplementation would improve attention in healthy middle-aged women.
Methods
A randomized, double-blind, placebo-controlled trial was conducted with 60 healthy women aged 40–60. Participants received either 250 mg/day or 500 mg/day of Cognizin® Citicoline or a placebo for 28 days. Cognitive performance was assessed using the Continuous Performance Test II (CPT-II), a validated measure of attentional function, at baseline and after 28 days.
Results
After 28 days, women taking Cognizin® Citicoline demonstrated:
- Fewer omission and commission errors on the CPT-II in the 250 mg group (vs. placebo)
- Significantly fewer commission errors in the 500 mg group (vs. placebo)
Conclusions
Daily supplementation with 250 mg or 500 mg of Cognizin® Citicoline for 28 days may improve attentional performance in healthy middle-aged women. Participants who received citicoline showed a better ability to produce correct responses on the CPT-II, likely due to improved cognitive inhibition. These findings suggest that Cognizin® may help support focus and cognitive control in this population.
